Advancing Science. Improving Connections.
Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare conditions
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual MeetingRead More
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsRead More
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg ConferenceRead More
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg ConferenceRead More